Taken RUNDC3A‐AS1, FOXD‐AS1, PAX8‐AS1, and CRYM‐AS1 for example, thyroid cancer patients with higher RUNDC3A‐AS1 or lower FOXD‐AS1 expression levels had shorter OS time, whereas thyroid cancer patients with higher PAX8‐AS1 or lower CRYM‐AS1 expression levels had shorter RFS time (Figure 3B,C). This evidence concerns the gene RUNDC3A and thyroid gland carcinoma.